Current evidence on diagnostic accuracy of commercially based nucleic acid amplification tests for the diagnosis of pulmonary tuberculosis S Greco, E Girardi, A Navarra, C Saltini Thorax 61 (9), 783-790, 2006 | 239 | 2006 |
Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study F Cantini, L Niccoli, C Nannini, D Matarrese, ME Di Natale, P Lotti, ... Journal of Infection 81 (4), 647-679, 2020 | 200 | 2020 |
Accuracy of immunodiagnostic tests for active tuberculosis using single and combined results: a multicenter TBNET-Study D Goletti, C Stefania, O Butera, M Amicosante, M Ernst, I Sauzullo, V Vullo, ... PloS one 3 (10), e3417, 2008 | 146 | 2008 |
COVID-19 disease—temporal analyses of complete blood count parameters over course of illness, and relationship to patient demographics and management outcomes in survivors and … S Lanini, C Montaldo, E Nicastri, F Vairo, C Agrati, N Petrosillo, ... PloS one 15 (12), e0244129, 2020 | 73 | 2020 |
Ageing with HIV: newly diagnosed older adults in Italy N Orchi, R Balzano, P Scognamiglio, A Navarra, G De Carli, P Elia, ... Aids Care 20 (4), 419-425, 2008 | 66 | 2008 |
Assessment of CD27 expression as a tool for active and latent tuberculosis diagnosis E Petruccioli, L Petrone, V Vanini, G Cuzzi, A Navarra, G Gualano, ... Journal of Infection 71 (5), 526-533, 2015 | 63 | 2015 |
Spike is the most recognized antigen in the whole-blood platform in both acute and convalescent COVID-19 patients A Aiello, SN Fard, E Petruccioli, L Petrone, V Vanini, C Farroni, G Cuzzi, ... International Journal of Infectious Diseases 106, 338-347, 2021 | 49 | 2021 |
Effect of HIV-infection on QuantiFERON-plus accuracy in patients with active tuberculosis and latent infection E Petruccioli, T Chiacchio, A Navarra, V Vanini, G Cuzzi, C Cimaglia, ... Journal of Infection 80 (5), 536-546, 2020 | 45 | 2020 |
Role of testosterone in SARS-CoV-2 infection: A key pathogenic factor and a biomarker for severe pneumonia M Camici, P Zuppi, P Lorenzini, L Scarnecchia, C Pinnetti, S Cicalini, ... International Journal of Infectious Diseases 108, 244-251, 2021 | 43 | 2021 |
Epidemiology of HEV in the Mediterranean basin: 10-year prevalence in Italy S Lanini, AR Garbuglia, D Lapa, V Puro, A Navarra, C Pergola, G Ippolito, ... BMJ open 5 (7), e007110, 2015 | 42 | 2015 |
Putting in harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for multidrug-resistant Tuberculosis. Experience from a tertiary … G Gualano, P Mencarini, M Musso, S Mosti, L Santangelo, S Murachelli, ... PloS one 14 (2), e0212948, 2019 | 32 | 2019 |
Characterization of variants in the promoter of EBV gene BZLF1 in normal donors, HIV-positive patients and in AIDS-related lymphomas M Martini, D Capello, D Serraino, A Navarra, F Pierconti, T Cenci, ... Journal of Infection 54 (3), 298-306, 2007 | 32 | 2007 |
High urine IP-10 levels associate with chronic HCV infection GD Petrone L, Chiacchio T, Vanini V, Petruccioli E, Cuzzi G, Di Giacomo C ... J Infect. 68 (6), 591-600, 2014 | 30 | 2014 |
Impact of hepatitis C virus infection on lifestyle P Scognamiglio, V Galati, A Navarra, MA Longo, MS Aloisi, MG Antonini, ... World Journal of Gastroenterology: WJG 13 (19), 2722, 2007 | 28 | 2007 |
Serum biomarker profile including CCL1, CXCL10, VEGF, and adenosine deaminase activity distinguishes active from remotely acquired latent tuberculosis EM Delemarre, L van Hoorn, AWJ Bossink, J Drylewicz, SA Joosten, ... Frontiers in immunology 12, 725447, 2021 | 27 | 2021 |
Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted to an Italian reference hospital A Mondi, P Lorenzini, C Castilletti, R Gagliardini, E Lalle, A Corpolongo, ... International Journal of Infectious Diseases 105, 532-539, 2021 | 25 | 2021 |
Burden and characteristics of the comorbidity tuberculosis—diabetes in Europe: TBnet prevalence survey and case-control study M Sane Schepisi, A Navarra, MN Altet Gomez, A Dudnyk, ... Open forum infectious diseases 6 (1), ofy337, 2019 | 25 | 2019 |
Use of several immunological markers to model the probability of active tuberculosis E Petruccioli, A Navarra, L Petrone, V Vanini, G Cuzzi, G Gualano, ... Diagnostic microbiology and infectious disease 86 (2), 169-171, 2016 | 24 | 2016 |
Exploratory analysis to identify the best antigen and the best immune biomarkers to study SARS-CoV-2 infection E Petruccioli, S Najafi Fard, A Navarra, L Petrone, V Vanini, G Cuzzi, ... Journal of translational medicine 19 (1), 272, 2021 | 23 | 2021 |
Characterization of QuantiFERON-TB-Plus results in latent tuberculosis infected patients with or without immune-mediated inflammatory diseases T Chiacchio, E Petruccioli, V Vanini, G Cuzzi, U Massafra, G Baldi, ... Journal of Infection 79 (1), 15-23, 2019 | 22 | 2019 |